# ESUR female pelvis group approach to cystic female pelvic lesions

**Authors:** Olivera Nikolić, Lucia Manganaro, Milagros Otero Garcia, Stephanie Nougaret, Isabelle Thomassin-Naggara, Refky Nicola, Nemanja Maletin, Charis Bourgioti

PMC · DOI: 10.1186/s13244-025-02174-4 · Insights into Imaging · 2026-02-16

## TL;DR

This paper reviews how to diagnose and differentiate cystic pelvic lesions in women using MRI, emphasizing the importance of accurate diagnosis for proper treatment.

## Contribution

The paper provides a comprehensive review of MRI characteristics of ovarian and non-ovarian pelvic lesions, emphasizing differential diagnosis and the use of the O-RADS MRI system.

## Key findings

- MRI is particularly useful for complex pelvic lesions due to its high soft tissue resolution and multiplanar imaging.
- Accurate diagnosis requires understanding pelvic anatomy, differential diagnoses, and clinical data integration.
- The O-RADS MRI system helps standardize communication and assess malignancy risk in ovarian cystic lesions.

## Abstract

Cystic female pelvic lesions, whether of ovarian or non-ovarian origin, are prevalent in routine clinical practice, with the majority originating from gynaecological (ovarian) structures, ranging from functional cysts to malignant ovarian tumours. Despite the fact that we encounter these lesions in the course of our routine clinical work, arriving at an accurate diagnosis can often prove challenging due to the overlap of imaging appearances. Ultrasound is the primary imaging modality for the evaluation of most cystic female pelvic lesions, while MRI serves as a problem-solving tool. In cases that are more complex or equivocal, pelvic MRI proved to be particularly useful due to its superior soft tissue resolution, multiplanar imaging capability and non-invasive nature. In order to make an accurate diagnosis, it is crucial to have a comprehensive understanding of pelvic topographic anatomy, be familiar with possible differential diagnoses and include all relevant clinical data. The classification of ovarian cystic lesions was undertaken using the O-RADS MRI risk stratification system, which provides standardised language for communication between radiologists and clinicians. The objective of this review is to illustrate the spectrum of typical MRI characteristics of different cystic female lesions of both ovarian and non-ovarian origin, with the emphasis on differential diagnoses. The review includes tables with MRI appearances on T2, T1, DWI sequences and postcontrast tomograms. To facilitate the learning process, schematic representations of MRI appearances of ovarian lesions have been incorporated.

MRI diagnosis of various ovarian and non-ovarian cystic female pelvic lesions and their differential diagnosis.

The diagnosis of cystic female pelvic lesions can be challenging due to the overlapping imaging characteristics exhibited by these lesions.Discrimination between ovarian and non-ovarian lesions is of paramount importance, given the existence of marked discrepancies in both prognosis and management.If the lesion is of ovarian origin, the O-RADS MRI risk stratification system should be implemented in order to ascertain the risk of malignancy.

The diagnosis of cystic female pelvic lesions can be challenging due to the overlapping imaging characteristics exhibited by these lesions.

Discrimination between ovarian and non-ovarian lesions is of paramount importance, given the existence of marked discrepancies in both prognosis and management.

If the lesion is of ovarian origin, the O-RADS MRI risk stratification system should be implemented in order to ascertain the risk of malignancy.

## Full-text entities

- **Diseases:** Multilocular cyst (MESH:C536591), cystadenofibroma (MESH:D062625), PFTC (MESH:D005185), imperforate hymen (MESH:C562397), ovarian hyperstimulation syndrome (MESH:D016471), Krukenberg tumour (MESH:D007725), leukocytosis (MESH:D007964), bone remodelling (MESH:D001847), Immature teratoma (MESH:D013724), Gartner duct cyst (MESH:D015529), Lymphangiomas (MESH:D008202), tubal pregnancy (MESH:D011274), PIC (MESH:D010538), mucinous adenocarcinomas (MESH:D002288), ipsilateral renal anomaly (OHVIRA) syndrome (MESH:D012078), infected (MESH:D007239), oedema (MESH:C536897), dyspareunia (MESH:D004414), pelvic pain (MESH:D017699), follicular (MESH:D005497), retention cysts (MESH:D016055), Colon cancer metastasis (MESH:D015179), PMP (MESH:D011553), endometrial cancer (MESH:D016889), Cystic female pelvic lesions (MESH:D052177), metastases (MESH:D009362), Cystic gastrointestinal stromal tumours (MESH:D046152), abnormal uterine bleeding (MESH:D014592), unilateral renal agenesis (MESH:D000075529), teratocarcinoma (MESH:D018243), appendicitis (MESH:D001064), epidermoid cysts (MESH:D004814), ascites (MESH:D001201), (Gartner) cyst (MESH:D003560), chronic pelvic pain (MESH:D011472), ductal breast carcinoma (MESH:D018270), ccRCC (MESH:D002292), cystic degeneration of subserous or broad ligament leiomyoma (MESH:D000082122), ulcerative colitis (MESH:D003093), GI tract (MESH:D014570), necrosis (MESH:D009336), adnexal/ovarian lesions (MESH:D010049), mucosal hyperplasia (MESH:D006965), squamous cell cancer (MESH:D018307), dermoid cysts (MESH:D003884), malformations (MESH:C564254), Endometrioid borderline ovarian neoplasm (MESH:D010051), constipation (MESH:D003248), Congenital uterine/vaginal malformations (MESH:D014627), tubal cystadenocarcinoma (MESH:D003536), gastrointestinal tumours (MESH:D005770), postoperative infections (MESH:D013530), female lesions (MESH:D005831), congenital urogenital abnormalities (MESH:D014564), left kidney agenesis (MESH:D007674), inflammatory bowel disease (MESH:D015212), abdominal mass (MESH:D000007), cervical, breast, colon, fallopian tube cancer (MESH:D001943), Pelvic haematoma (MESH:D034161), Degenerative (hydropic) leiomyoma (MESH:D007889)
- **Chemicals:** T1 (MESH:C103828), 18-FDG (MESH:D019788), DCE (-), lipid (MESH:D008055), Gadolinium (MESH:D005682), Fat (MESH:D005223), iron (MESH:D007501)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12909720/full.md

## Figures

16 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12909720/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12909720/full.md

---
Source: https://tomesphere.com/paper/PMC12909720